Kate Madden Yee[email protected]SequencingCRISPR-based technology shows promise for oral health assessmentCRISPR-based technology could be used to assess a range of oral and systemic diseases, say researchers from the Forsyth Institute.May 16, 2023Lung CancerBiomarker data improves CT lung cancer screening's bottom lineThe findings suggest a way to make CT lung cancer screening not only more useful but also economical when it comes to patient outcomes, wrote a team led by Zixuan Zhao, PhD, of Zhejiang University in Hangzhou, China.May 23, 2022CarcinomaNIH launches molecular typing program of childhood cancersThe service is being conducted through NCI's Childhood Cancer Initiative, which began in 2019. Participants will receive a free molecular characterization of their tumors, including analysis of DNA and RNA taken from tumor and blood samples. The initiative will expand later this year to include soft-tissue carcinomas, the NIH said.March 20, 2022Moderate Complexity TestArticle supports FDA review of lab-developed testsThe U.S. Department of Health and Human Services (HHS) in August 2020 ruled that LDTs to diagnose whether patients are infected with SARS-CoV-2 did not have to undergo review by the FDA.March 7, 2022CollaborationPresidential panel sounds alarm on gaps in cancer screeningUnderutilization of cancer screening is a serious problem, wrote Dr. John Williams of George Mason University in Gainesville, VA; Dr. Edith Mitchell of Thomas Jefferson University in Philadelphia; and Robert Ingram of Hatteras Venture Partners in Durham, NC, in a letter to President Joe Biden included in the report.February 3, 2022Prostate CancerNew blood test for prostate cancer screening reduces MRIThe findings could translate to better prostate cancer screening, said study contributing author Martin Eklund, PhD, of the Karolinska Institute in Stockholm, in a statement released by the institute. The research team was led by Dr. Tobias Nordström, PhD, also of Karolinska.August 12, 2021InfectiousFDA authorizes Abbott's COVID-19 real-time antigen test"This new COVID-19 antigen test is an important addition to available tests because the results can be read in minutes, right off the testing card," said Dr. Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, in a statement released by the FDA. "This means people will know if they have the virus in almost real-time."August 26, 2020Ovarian CancerHealthy Nevada Project: Community genetic testing neededThe study, conducted by researchers from the Healthy Nevada Project, focused on identifying carriers of hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia.July 28, 2020InflammationCOVID-19 patients at risk for heart complicationsThe study findings suggest yet another facet of the illness that must be tracked, wrote a team led by Dr. Valentina Puntmann, PhD, of University Hospital Frankfurt in Germany.July 27, 2020Emergency Use AuthorizationFDA clears LabCorp's COVID-19 test for asymptomatic useThe agency renewed emergency use authorization (EUA) for LabCorp's assay with two new applications: testing asymptomatic individuals and allowing for pooled testing with up to five individual swab specimens.July 26, 2020Page 1 of 4Next PageTop StoriesFDA ClearanceAmgen gets FDA approval for small cell lung cancer therapyAmgen announced on Thursday that the U.S. Food and Drug Administration (FDA) has approved its therapy tarlatamab, to be marketed under the name Imdelltra, for the treatment of extensive-stage small cell lung cancer (ES-SCLC).Artificial IntelligenceBacklog of unresolved medical diagnoses leads to new method for clinical exome reanalysisStockT2 Biosystems to sell $8M in stock in private placementFDA Warning LetterFDA issues warning for Cue Health COVID-19 testsSponsor ContentVisit our Molecular Diagnostics Community
